NCT05643469 Self-determination Plus Instant Messaging for Smokers With Cancer
| NCT ID | NCT05643469 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Smoking |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,448 participants |
| Start Date | 2023-07-03 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,448 participants in total. It began in 2023-07-03 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objective: To test the efficacy of a self-determination theory-based intervention plus instant messaging to help smokers with cancer quit smoking. Hypothesis to be tested: Subjects who are allowed to choose their quit schedule and receive regular instant messaging about smoking cessation will show a significantly higher biochemically validated quit rate than those who receive only brief advice to quit immediately. Design and Subjects: An RCT will be conducted to 1448 smokers with cancer attending the outpatient clinics of five major acute care hospitals in Hong Kong for medical follow-up. Instruments: A structured questionnaire will be used to assess subjects' smoking history and demographic and clinical characteristics. EQ-5D-5L will be used to measure subjects' quality of life. Interventions: The intervention group will receive brief advice and will be invited to choose their own quit schedules (immediate or progressive) in the outpatient clinics. They will receive instant messaging about smoking cessation during the first 6-month follow-up period. The control group will receive brief advice to quit smoking immediately in the outpatient clinics, and will receive a placebo intervention during the first 6-month follow-up period. Subjects in both groups will receive leaflets on smoking cessation.
Eligibility Criteria
Inclusion Criteria: * smoked weekly in the last 6 months, * diagnosed with any cancer for at least 6 months and at all cancer stages (I, II, III, or IV), * aged 18 years or above and can communicate in Cantonese, and * own a smartphone and able to use instant messaging (e.g. WhatsApp or WeChat) Exclusion Criteria: * individuals with unstable medical conditions, poor cognitive state, or mental illness as advised by the doctor in charge and noted on their medical records, and * those participating in other smoking cessation programmes.
Contact & Investigator
Ho Cheung William Li, PhD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05643469 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05643469 currently recruiting?
Yes, NCT05643469 is actively recruiting participants. Contact the research team at williamli@cuhk.edu.hk for enrollment information.
Where is the NCT05643469 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05643469 clinical trial?
NCT05643469 is sponsored by Chinese University of Hong Kong. The principal investigator is Ho Cheung William Li, PhD at Chinese University of Hong Kong. The trial plans to enroll 1,448 participants.